Close Menu
    Health

    HER2-positive breast cancer: How targeted therapy changed outcomes

    Health DeskBy 4 Views
    HER2-positive breast cancer

    The short answer: HER2-positive breast cancer was once one of the most aggressive and deadly forms of the disease. The introduction of trastuzumab, the first HER2-targeted drug, in the late 1990s transformed outcomes. Before trastuzumab, HER2-positive breast cancer had a poor prognosis with high recurrence rates [2]. After trastuzumab became standard treatment, recurrence and death rates fell dramatically [9][15]. Today, newer drugs including pertuzumab, T-DM1, and trastuzumab deruxtecan have pushed survival even further. In 2025, the FDA approved trastuzumab deruxtecan plus pertuzumab for first-line metastatic HER2-positive breast cancer, showing a median progression-free survival of 40.7 months compared with 26.9 months for the previous standard [10][17].

    HER2-positive breast cancer accounts for approximately 20% of all breast cancers [4]. The HER2 protein, when overexpressed, drives rapid cancer cell growth. Before targeted therapy existed, this subtype had one of the worst prognoses. The story of HER2-targeted therapy is one of the most dramatic successes in modern oncology.

    The pre-trastuzumab era: a poor prognosis

    Before trastuzumab, HER2-positive breast cancer was associated with particularly aggressive disease and poor outcomes. A 2007 review explained that in the pre-trastuzumab era, HER2 overexpression was an adverse prognostic factor linked to increased risk of disease recurrence and death [2].

    A real-world observational study called RETROHER compared outcomes in the pre-trastuzumab and trastuzumab eras. It analyzed 925 HER2-positive early breast cancer patients treated in ten Italian oncologic centers. Patients who received adjuvant chemotherapy alone had significantly worse relapse rates at 3 years, relapse-free survival, and overall survival compared with those who received trastuzumab [9].

    The authors noted that trastuzumab’s benefit was independent of nodal status and hormone receptor expression [9].

    The trastuzumab revolution

    Trastuzumab is a monoclonal antibody that binds to the HER2 receptor and blocks its signaling. It was the first targeted therapy approved for HER2-positive breast cancer.

    The natural history of HER2-positive early breast cancer was dramatically changed in 2005 by four randomized phase III trials: HERA, BCIRG-006, NCCTG 9831, and NSABP-B31. These trials established one year of adjuvant trastuzumab as the standard of care. Long-term follow-up (8 to 11 years) confirmed significant and prolonged improvement in outcomes [1].

    Despite these improvements, HER2-positive patients still relapse in significant numbers. The 11-year follow-up of HERA showed that approximately 30% of patients in the trastuzumab arms eventually experienced a relapse [1].

    Dual blockade: adding pertuzumab

    The next advance was dual HER2 blockade. Pertuzumab is another monoclonal antibody that binds to a different part of the HER2 receptor, preventing it from pairing with other HER receptors.

    The APHINITY trial tested chemotherapy plus trastuzumab or trastuzumab plus pertuzumab for one year in 4,805 patients. The dual blockade arm showed a statistically significant improvement in invasive disease-free survival. The absolute gain was 0.9% at 3 years and 1.7% at 4 years. Patients with node-positive disease benefited more [1].

    The NEOSPHERE study tested dual blockade in the neoadjuvant setting and showed superior pathologic complete response rates compared with single blockade, with an absolute improvement of approximately 16% [1].

    Ten-year survival with dual blockade

    A 2023 study published in the Mayo Clinic Proceedings reported ten-year survival outcomes from the NeoALTTO trial, which tested lapatinib and/or trastuzumab in HER2-positive early breast cancer [8].

    Ten-year event-free survival estimates were 63% for lapatinib, 64% for trastuzumab, and 67% for the combination. Ten-year overall survival rates were 76%, 75%, and 80% respectively. Women who achieved a pathologic complete response had significantly better outcomes, with a hazard ratio of 0.48 for event-free survival and 0.37 for overall survival compared with those who did not [8].

    The study concluded that patients with HER2-positive breast cancer showed durable survival benefit from neoadjuvant anti-HER2 therapy [8].

    Antibody-drug conjugates: a new class

    The newest class of HER2-targeted drugs is antibody-drug conjugates (ADCs). These drugs combine a targeted antibody with a potent chemotherapy payload, delivering the toxic drug directly to cancer cells.

    Trastuzumab emtansine (T-DM1) was the first HER2 ADC approved. Trastuzumab deruxtecan (T-DXd) is a newer ADC with a higher drug-to-antibody ratio and a membrane-permeable payload.

    A 2025 systematic review and meta-analysis of four randomized controlled trials (DESTINY-Breast02, -03, -04, and -06; 2,555 patients) found that T-DXd significantly improved progression-free survival (hazard ratio 0.433) and overall survival (hazard ratio 0.720) compared with control regimens in both HER2-high and HER2-low breast cancer [4].

    However, T-DXd increased the risk of interstitial lung disease (relative risk 13.832) and decreased left ventricular ejection fraction (relative risk 2.247) [4]. These risks require monitoring.

    The 2025 breakthrough: DESTINY-Breast09

    In December 2025, the FDA approved trastuzumab deruxtecan plus pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. The approval was based on the phase III DESTINY-Breast09 study [10][17].

    The trial randomized patients to receive T-DXd plus pertuzumab or the standard of care THP (trastuzumab, pertuzumab, and a taxane). Median progression-free survival was 40.7 months with T-DXd plus pertuzumab compared with 26.9 months for THP. The risk of disease progression or death was reduced by 44% [10][17].

    The confirmed objective response rate was 87% with T-DXd plus pertuzumab compared with 81% with THP. Fifteen percent of patients on the T-DXd combination experienced complete responses, in which their cancer disappeared [10].

    Dr. Sara Tolaney of Dana-Farber Cancer Institute, the principal investigator, stated: “T-DXd plus pertuzumab is the only first-line treatment approved in more than a decade to demonstrate a statistically significant improvement in progression-free survival over the current standard regimen” [10].

    The access gap

    The benefits of HER2-targeted therapy have not reached all patients equally. The Advanced Breast Cancer Global Decade Report 2015-2025 found that trastuzumab, a widely recognized standard of care for HER2-positive advanced breast cancer, is accessible in only about half of low- and middle-income countries, compared with nearly all high-income nations [12].

    The report also noted that nearly four in five people with advanced breast cancer have never participated in a clinical trial [12]. The WHO has documented that availability of essential cancer medicines ranges from only 9% to 54% in low- and lower-middle-income countries, compared with 68% to 94% in high-income countries [5].

    The South African breast cancer policy document notes that the costs of HER2-targeted treatments limit accessibility worldwide, and recommends negotiations with pharmaceutical providers for costs that do not compromise care provision in other sectors [6].

    What is myth, not documented

    Myth: HER2-positive breast cancer is still a death sentence. The evidence shows dramatic improvement in outcomes. Ten-year overall survival rates of 75% to 80% have been reported in clinical trials [8]. Real-world data from Brazil confirms significantly better survival with trastuzumab compared with other therapies [15].

    Myth: All HER2-targeted drugs work the same way. Trastuzumab and pertuzumab are monoclonal antibodies that block HER2 signaling. T-DM1 and T-DXd are antibody-drug conjugates that deliver chemotherapy directly to cancer cells. Lapatinib is a small molecule tyrosine kinase inhibitor. They have different mechanisms and different side effect profiles [6].

    Myth: T-DXd is safe with no serious side effects. The meta-analysis found that T-DXd significantly increased the risk of interstitial lung disease and decreased left ventricular ejection fraction [4]. These risks require monitoring and management.

    The bottom line

    HER2-positive breast cancer has been transformed from one of the most aggressive subtypes to one with multiple effective treatment options. Trastuzumab changed the natural history of the disease [2]. Pertuzumab added further benefit through dual blockade [1]. Trastuzumab deruxtecan, an antibody-drug conjugate, has pushed survival even further, with a median progression-free survival exceeding three years in first-line metastatic disease [10][17]. The challenge now is ensuring that these advances reach patients in all countries, not just high-income settings [12].

    Disclaimer

    This article is for informational purposes only and is not a substitute for professional medical advice. If you have been diagnosed with HER2-positive breast cancer, discuss your treatment options with a qualified healthcare provider. We welcome your feedback and corrections. Please contact us if you notice any errors.

    References

    Share.

    Health Desk publishes educational health information based on medical and public-health sources. Our articles are intended for general information and do not replace professional medical advice, diagnosis or treatment. Readers are encouraged to consult qualified healthcare professionals regarding personal health concerns. Corrections and feedback are welcome through our contact page. To advertise with us or support our cause through a donation, reach out via our contact page or email: hello@trenderhq.com

    Related Posts

    Leave A Reply

    TrenderHQ © 2026 | powered by Intek Multimedia.